

SYNTHESIS OF BIOLOGICALLY ACTIVE PRIMANES FROM (-)-SCLAREOL

Alejandro F. Barrero,* Enrique Alvarez-Manzaneda, Joaquín Altarejos, Sofía Salido
and José M. Ramos

*Departamento de Química Orgánica, Facultad de Ciencias, Universidad de Granada,
18071 Granada (Spain)*


Key Words: Sclareol, drimane, osmium tetroxide, ozonolysis.

Abstract: The enantiospecific synthesis of drimenyl acetate (8), a key intermediate in the synthesis of biologically active drimanes, and albicanyl acetate (14), potent fish antifeedant, from sclareol (1), are described. Also a short and efficient synthesis of polygodial (22), from albicanyl acetate (14), is shown.

A number of drimane sesquiterpenes showing interesting biological activity occur in nature.¹ Because of this, different procedures for their preparation have been described.² In this paper the synthesis of drimenyl acetate (**8**) and albicanyl acetate (**14**) from sclareol are presented. Albicanyl acetate is a potent fish antifeedant³ and has been used by the authors in the synthesis of polygodial (**22**).¹

The oxidation of sclareol (**1**) with osmium tetroxide-sodium periodate leads to the acetoxyaldehyde **2** in 73% yield, which besides being an intermediate in the synthesis of Ambrox®,⁴ can be transformed into drimenyl acetate (**8**) in three simple steps in high overall yield. **8** has been used in the preparation of polygodial (**22**),⁵ warbuganal (**23**)⁶ and ugandensidial (**24**).⁷ The treatment of **2** with *tert*-butyldimethylsilyl chloride in dichloromethane, gives quantitative yields of the corresponding silyl enol ethers (**3a** and **3b**),⁸ which after ozonolysis and subsequent reduction with sodium borohydride, lead to the acetoxyalcohol **6** in 95% yield (schemes 1 and 2).


Scheme 1



a) OsO₄/NaIO₄, PrⁱOH, 45°C, 6 h, 73%; b) Cl-TBDMS, tNa, THF, -78°C, 4 h, 99%; c) Ac₂O, Et₃N, 4-DMAP, THF, reflux, 18 h, 89%.

The use of the silyl enol ethers **3a** and **3b** improves considerably the yield of this transformation in comparison with the use of the corresponding enol acetates (**4a** and **4b**),⁹ with which the yield is 64%. This is because the triacetate **5**¹⁰ is obtained in the acetylation step, and the ozonolysis produces the stereospecific degradation of the enol acetate *E* (**4a**), while the isomer *Z* (**4b**) remains unaltered. The dehydration of the acetoxyalcohol **6** with POCl_3 in Py, and MsCl , Et_3N , DMAP in dichloromethane is not regioselective and gives equimolar mixtures of the isomers Δ^7 , Δ^8 y Δ^8 .¹² However the use of SnCl_4 in dichloromethane allows the transformation of **6** into drimenyl acetate (**8**) as the main product, in 61% yield (scheme 2).


Scheme 2



a) O_3 , $\text{MeOH}/\text{CH}_2\text{Cl}_2$, -78°C , 1 h; b) NaBH_4 , MeOH , rt, 30 min, 95%; c) LiAlH_4 , MeOH , rt, 40 min, 95%; d) Cl_4Sn , CH_2Cl_2 , -19°C , dropwise 30 min, 61%; e) Cl-TBDMS , 4-DMAP, Et_3N , CH_2Cl_2 , rt, 2 h, 99%.

The silyl derivatives **3a** and **3b** can be employed as precursors for other drimanes of interest, such as (+)-drim-9(11)-en-8-ol (**11**), isolated from the fungus *Aspergillus oryzae*¹¹ which is used in the manufacture of certain Japanese drinks such as "sake", "tamari" and "shoyu". The ozonolysis of mixture **3a** and **3b**, and subsequent reduction with lithium aluminium hydride gives 95% of the diol **7**, as shown in scheme 2, whose transformation to **11** has been previously described¹² (scheme 3).


Scheme 3



a) TsCl , Py, 4-DMAP; b) NaI , Zn .

The acetylation of **6** gives the diacetate **12** in 92% yield, which converts almost quantitatively into an equimolecular mixture of **14** and **16** by heating with collidine. The elimination of acetate can be regioselective to $\Delta^8,12$ using the silyl derivative **13** instead of the corresponding diacetate **12**, in which case the ratio of **15:17** is 2:1 (scheme 4).


Scheme 4



a) Ac_2O , Et_3N , 4-DMAP, THF, reflux, 18 h, 92%; b) collidine, reflux, 8 h, 99%.

The oxidation of albicanyl acetate (**14**) with SeO_2 and Bu^tOOH in dichloromethane, allows the regio and diastereoselective hydroxylation at the 7α position, yielding **18** in 85%. By the treatment of **18** with MsCl in Py and further solvolysis of the mesylate **19**, a 67% of **20** is obtained, which saponifies to give the diol **21**. This is converted in polygodial (**22**) (92%) by oxidation with Swern's reagent (scheme 5).

Scheme 5



a) SeO_2 , Bu^tOOH , CH_2Cl_2 , rt, 4 h, 85%; b) MsCl , Py, rt, 30 min, 98%; c) NaOAc , H_2O , acetone, reflux, 2 h, 69%; d) KOH/MeOH 2N, 2 h, 95%; e) $(\text{CICO})_2$, DMSO , CH_2Cl_2 , Et_3N , -78°C , 15 min, 92%.

Acknowledgements

We wish to thank to the DGICYT for the financial support: Projet PB 92-0942.

To Mr. William Taylor by the translation of this paper.

References and notes

- 1- Jansen, B.J.M.; de Groot, A. *Nat. Prod. Rep.* **1991**, *8*, 309-318.
- 2- Jansen, B.J.M.; de Groot, A. *Nat. Prod. Rep.* **1991**, *8*, 319-337.
- 3- Hellou, J.; Andersen, R.J.; Thomson, J.E. *Tetrahedron* **1982**, *38*, 1875-1879.
- 4- Barrero, A.F.; Alvarez-Manzaneda, E.J.; Altarejos, J.; Salido, S.; Ramos, J.M. *Tetrahedron* **1993**, *49*, 10405-10412.
- 5- Cortés, M.J.; Razmilic, I.; Sierra, J.R.; López, J. *Chem. Ind.* **1985**, 735.
- 6- Oyarzun, M.L.; Cortés, M.; Sierra, J. *Synth. Commun.* **1982**, *12*, 951-958.
- 7- Cortés, M.J.; Razmilic, I.; López, J. *J. Nat. Prod.* **1990**, *53*, 1369-1371.
- 8- *8α-acetoxy-12-t-butylidemethylsilyloxy-13,14,15,16-tetranorlabd-11E/Z-ene (3a, 3b)* (4:1): ¹H-NMR (80 MHz): signals assignable to **3b** 0.11 (6 H), 0.73 (3 H), 0.86 (6 H), 0.91 (9 H), 1.41 (3 H), 1.81 (3 H), 2.97 (1 H, *d*, 10.6), 4.36 (1 H, *dd*, 10.6, 6.4), 6.31 (1 H, *d*, 6.4). The recrystallisation in methanol of the mixture of silyl enol ethers allows purification to the isomer **3a**: ¹H-NMR (300 MHz): 0.12 (6 H), 0.77 (3 H), 0.86 (6 H), 0.91 (9 H), 1.40 (3 H), 1.88 (3 H), 2.23 (1 H, *d*, 11.1), 2.40 (1 H, *dt*, 12.7, 3.4, 3.4), 4.94 (1 H, *t*, 11.1), 6.14 (1 H, *d*, 11.1); ¹³C-NMR (75 MHz): 38.03 (C1), 18.32 (C2), 41.82 (C3), 33.12 (C4), 56.36 (C5), 19.91 (C6), 40.62 (C7), 86.00 (C8), 55.15 (C9), 37.92 (C10), 106.47 (C11), 142.76 (C12), 22.85 (C17), 33.19 (C18), 21.44 (C19), 15.97 (C20), 21.37 (AcO-C8), 170.12 (AcO-C8), 14.01 (C1'y C2'), 25.67 (C1", C2" y C3").
- 9- *8α,12-diacetoxy-13,14,15,16-tetranorlabd-11(E/Z)-ene (4a, 4b)* (3:1): IR (film): 1757, 1725, 1668, 1253, 940, 886, 803 cm⁻¹; ¹H-NMR (300 MHz): signals assignable to **4a** and **4b** 0.78 (3 H), 0.85 (3 H), 0.87 (3 H), 1.42 (3 H), 2.44 (1 H, *dt*, 12.8, 3.3, 3.3), signals assignable to **4a** 1.90 (3 H), 2.10 (3 H), 2.34 (1 H, *d*, 11.1), 5.38 (1 H, *dd*, 12.2, 11.1), 7.00 (1 H, *d*, 12.2), signals assignable to **4b** 1.82 (3 H), 2.14 (3 H), 3.08 (1 H, *d*, 11.0), 4.90 (1 H, *dd*, 11.0, 6.7), 7.11 (1 H, *d*, 6.7); ¹³C-NMR (75 MHz): isomer **4a** 40.76 (C1), 18.37 (C2), 41.86 (C3), 33.28 (C4), 55.17 (C5), 20.01 (C6), 38.26 (C7), 85.38 (C8), 52.68 (C9), 37.91 (C10), 110.31 (C11), 137.92 (C12), 22.86 (C17), 33.33 (C18), 21.55 (C19), 16.05 (C20), 168.12 (AcO-C8), 170.38 (AcO-C12), isomer **4b** 39.95 (C1), 18.37 (C2), 41.86 (C3), 33.28 (C4), 56.69 (C5), 20.10 (C6), 38.08 (C7), 85.72 (C8), 52.01 (C9), 38.42 (C10), 110.45 (C11), 136.67 (C12), 22.86 (C17), 33.33 (C18), 21.44 (C19), 15.62 (C20), 168.12 (AcO-C8), 178.38 (AcO-C12).
- 10- *8α,12,12-triacetoxy-13,14,15,16-tetranorlabdane (5)*: ¹H-NMR (300 MHz): 0.77 (3 H), 0.81 (3 H), 0.85 (3 H), 1.47 (3 H), 1.98 (3 H), 2.06 (3 H), 2.09 (3 H), 2.62 (1 H, *dt*, 12.6, 3.3, 3.3,), 6.97 (1 H, *dd*, 7.2, 5.6,); ¹³C-NMR (75 MHz): 39.56 (C1), 18.33 (C2), 41.67 (C3), 33.20 (C4), 56.39 (C5), 19.86 (C6), 38.45 (C7), 86.76 (C8), 52.60 (C9), 38.87 (C10), 29.72 (C11), 91.63 (C12), 21.93 (C17), 33.29 (C18), 21.45 (C19), 15.67 (C20), 20.97* (AcO-C8), 170.26 (AcO-C8), 20.71* (AcO y AcO'-C12), 169.22# (AcO-C12), 169.80# (AcO'-C12).
- 11- Wada, K.; Tanaka, S.; Marumo, S. *Agric. Biol. Chem.* **1983**, *47*, 1075-1078.
- 12- Shishido, K.; Omodani, T.; Shibuya, M. *J. Chem. Soc., Perkin Trans. I* **1991**, 2285-2287.

* These assignments may be interchanged.

These assignments may be interchanged.

(Received in UK 31 December 1993; revised 21 February 1994; accepted 25 February 1994)